Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Pharma Wins Approval for Generic Diuretic

publication date: Jan 30, 2008

China Pharma Holdings, Inc. received SFDA approval for a generic version of Bumetanide injection, a diuretic that is given for a wide variety of indications. The company said the approval shows the SFDA has now adjusted to the new drug approval regulations implemented on October 1, 2007, and is, once again, completing new drug applications. The Bumetanide ruling bodes well for other drugs that China Pharma has submitted for approval. The company's income statement is strong, but its balance sheet has some issues. More details...

Stock Symbol: (OTCBB: CPHI)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital